134 related articles for article (PubMed ID: 20479095)
1. Clopidogrel poor metabolizers may need alternative to standard regimen.
Thompson CA
Am J Health Syst Pharm; 2010 May; 67(10):779-80. PubMed ID: 20479095
[No Abstract] [Full Text] [Related]
2. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
Smock KJ; Saunders PJ; Rodgers GM; Johari V
Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
[TBL] [Abstract][Full Text] [Related]
3. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
Gurbel PA; Tantry US
JACC Cardiovasc Interv; 2010 Oct; 3(10):1008-10. PubMed ID: 20965457
[No Abstract] [Full Text] [Related]
4. Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Jeong YH; Park Y; Muse WC; Kwon TJ; Koh JS; Hwang SJ; Kwak CH; Hwang JY
J Thromb Haemost; 2012 Aug; 10(8):1685-8. PubMed ID: 22612904
[No Abstract] [Full Text] [Related]
5. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
[TBL] [Abstract][Full Text] [Related]
6. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
Angiolillo DJ; Ueno M
JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
[No Abstract] [Full Text] [Related]
7. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
9. In brief: poor metabolizers of clopidogrel (plavix).
Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
[No Abstract] [Full Text] [Related]
10. Clopidogrel: to test or not to test? That is the question--still.
Cannon CP
Clin Chem; 2011 May; 57(5):659-61. PubMed ID: 21402801
[No Abstract] [Full Text] [Related]
11. Current status of clopidogrel pharmacogenomics.
Giusti B; Gori AM; Marcucci R; Abbate R
Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
[No Abstract] [Full Text] [Related]
12. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.
Tousoulis D; Siasos G; Zaromitidou M; Oikonomou E; Maniatis K; Kioufis S; Kokkou E; Papavassiliou AG; Stefanadis C
Int J Cardiol; 2013 Sep; 168(2):1594-6. PubMed ID: 23402725
[No Abstract] [Full Text] [Related]
13. Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.
Roden DM; Shuldiner AR
Circulation; 2010 Aug; 122(5):445-8. PubMed ID: 20585014
[No Abstract] [Full Text] [Related]
14. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
Perry E
Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
[No Abstract] [Full Text] [Related]
15. Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T; Miyata T
Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
George J; Doney A; Palmer CN; Lang CC
Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
[No Abstract] [Full Text] [Related]
17. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
Kim KA; Park PW; Hong SJ; Park JY
Clin Pharmacol Ther; 2008 Aug; 84(2):236-42. PubMed ID: 18323861
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
Simon T; Bhatt DL; Bergougnan L; Farenc C; Pearson K; Perrin L; Vicaut E; Lacreta F; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
[TBL] [Abstract][Full Text] [Related]
19. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
20. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.
; ; ; Holmes DR; Dehmer GJ; Kaul S; Leifer D; O'Gara PT; Stein CM
Circulation; 2010 Aug; 122(5):537-57. PubMed ID: 20585015
[No Abstract] [Full Text] [Related]
[Next] [New Search]
